[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-disorders":494},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,43,55,83,126,164,189,217,240,273,309,330,359,385,413,440,469],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053739",false,"NCT07388537","Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age 8 years to 65 years\n2. Meet at least one of the following:\n\n   a. Overweight\u002FObesity:\n\n   i. For participants under 18 years of age: BMI \\>= 85th percentile for age and sex\n\nii. For participants \\>= 18 years of age: BMI \\>= 25 kg\u002Fm\\^2 (\\>=23 kg\u002Fm\\^2 for self-reported Asian race\u002Fethnicity)\n\nb. Suspected or evidence of hyperglycemia:\n\ni. Diagnosis of prediabetes or diabetes in medical history or by participant\u002Fguardian\u002FLegally Authorized Representative (LAR) report, OR\n\nii. Fasting blood glucose \\>= 100 mg\u002FdL in medical record, OR\n\niii. Postprandial blood sugar \\>= 140 mg\u002FdL in medical record, OR\n\niv. Hemoglobin A1c \\>= 5.7% in medical record\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of significant medical illnesses that the investigators feel may interfere with potential evaluations, i.e. individuals who are critically ill, unstable, or with severe organ failure that may affect\u002Flimit the endocrine evaluation and place unsustainable demands on Clinical Center or NIDDK resources.\n2. History of any medical, psychiatric, or social conditions which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the participant.\n3. Inability or unwillingness of participant, parent\u002Fguardian, or LAR to provide informed consent.","ALL","8 Years","65 Years",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nDiabetes and obesity are chronic diseases. They can affect blood flow and how the body processes nutrients, and complications over time can lead to early death. Diabetes can affect children as well as adults, but the disease seems to be more severe and to progress faster when it appears in younger people. Researchers want to understand more about how diabetes and obesity develop and change over time.\n\nObjective:\n\nTo collect data and samples regularly from people with obesity and diabetes.\n\nEligibility:\n\nPeople aged 8 to 65 years. They must be overweight or obese; or have high blood sugar; or have problems with how their body uses food for energy.\n\nDesign:\n\nParticipants will have additional procedures during routine care visits at the NIH clinic.\n\nData collected for the study will include the following:\n\nInformation from the participant s medical chart will be kept for research.\n\nQuestionnaires will ask about participant s eating habits, feelings, sleep, and substance use. They will take 30 to 60 minutes. Care providers will address any issues revealed in these surveys.\n\nBlood, saliva, urine, and stool samples will be collected. Samples may be used for genetic tests.\n\nData and samples will be kept for future research.\n\nParticipants may remain in the study up to 30 years.",[23,24,25],"Obesity","Diabetes","Metabolic Disorders",[27,23,28,29],"Clinical Spectrum of Diabetes","Hyperglycemia","Metabolic Disease","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":19},"2026-07-16",{"date":38,"type":19},"2055-04-30",{"name":40,"class":41},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":44,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":46,"keywords":47,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":42},"100622816",{"count":18,"type":19},[23,24,25],[27,23,28,29],"2026-07-01",{"date":50,"type":34},"2026-07-02",{"date":52,"type":19},"2026-07-07",{"date":38,"type":19},{"name":40,"class":41},{"id":56,"slug":4,"hasResults":10,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":14,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":42},"100469897","NCT05398783","A Natural History Study of Metabolic Sizing in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all the following criteria for their cohort:\n\nCohort 1 - Healthy Volunteers\n\n* Male or female, aged \\>=2 years\n* In good general health as evidenced by medical history\n\nCohort 2 - Patients\n\n* Male or female, aged \\>=2 years\n* Diagnosed with diseases thought to alter metabolism or body composition (such as weight loss or gain, diabetes, renal disease, obesity, cancer, etc.) or taking medications thought to alter metabolism or body composition.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Participants over 200 kg due to the weight limit of the equipment.\n* Presence of any implanted device that would interfere with measurements.\n* Any moderate to severe limitations in mobility that would impede participation\n* Hemoglobin less than 10 g\u002FdL (in participants who would have blood drawn for research purposes).\n* Participants with dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals.\n* Participants unwilling or unable to give informed consent.\n* Participants with any other significant physical, medical, or psychiatric limitations, illness or conditions that may preclude them from completing the majority of the tests in this study per the discretion of the PI.",true,"2 Years","99 Years",{"count":64,"type":19},2000,"Background:\n\nScientists have long used simple measures (such as height and weight) to estimate how much a person s body uses food (calories) as energy, as commonly called the metabolic rate. But metabolism varies among people with similar body sizes. Scientists now believe the old formulas for estimating metabolic rates may not work well for all people. Researchers want to find more accurate ways to measure a person s metabolism.\n\nObjective:\n\nThis natural history study will examine the relationships between metabolism, body composition, and body surface area in a wide range of people.\n\nEligibility:\n\nHealthy children and adults aged 2 years or older. Also, people aged 2 years or older with conditions that may alter metabolism. These may include diabetes, obesity, renal disease, or cancer.\n\nDesign:\n\nParticipants will spend 2 days and 1 night in the hospital. They will provide a medical history and answer questions about their activity levels, the foods they eat, and their lifestyle. They will also eat a special diet.\n\nParticipants will undergo many tests:\n\nThey will lie in a bed with a clear hood covering their head for 30 to 45 minutes to measure the gases in their breath.\n\nThey will lie on a padded table for about 15 minutes while their body is scanned.\n\nThey will stand on a platform while a 3D scanner measures their body.\n\nThey will have a test to measure how fast an electric signal moves through their body.\n\nThey will grip an instrument to measure the strength of their hands.\n\nThey will drink salty water and provide blood and urine samples.\n\nParticipants may be invited to return for these 2-day visits up to 8 times per year. Return visits must be at least 2 weeks apart.",[25,67,68,24,69],"Cancer","Chronic Kidney Disease","Normal Physiology",[71,72,73,74],"Body Composition","Metabolism","Body Surface Area","Natural History","RECRUITING","2026-06-30",{"date":48,"type":34},{"date":79,"type":34},"2022-10-25",{"date":81,"type":19},"2031-07-01",{"name":40,"class":41},{"id":84,"slug":4,"hasResults":10,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":10,"sex":14,"minAge":90,"maxAge":16,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100637347","NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","18 Years",{"count":92,"type":19},130,"INTERVENTIONAL",[95],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[98,99,100,25,101,102,103,104,105,106,107,108,109,110,111,112],"Diabetes Mellitus, Type 2","Diabetes Melletus","Glucose Metabolism Disorders","Nutritional and Metabolic Diseases","Endocrine System Diseases","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[114,105],"Ramadan","2026-06-18",{"date":117,"type":34},"2026-06-23",{"date":119,"type":19},"2026-07",{"date":121,"type":19},"2027-05",{"name":123,"class":124},"Eli Lilly and Company","INDUSTRY",37,{"id":127,"slug":4,"hasResults":10,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":10,"sex":14,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":93,"phases":137,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100295674","NCT03128996","Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","A Phase I\u002FII Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders","FAM BMT","Inclusion Criteria:\n\n* Nonmalignant disorder requiring bone marrow transplant including bone marrow failure syndromes, metabolic disorders, immunologic disorders, or hemoglobinopathy\n* For patients with sickle cell disease, must have one of the following severe manifestations:\n\n  1. Overt or silent stroke or persistently elevated transcranial doppler velocities despite transfusion therapy\n  2. Recurrent acute chest syndrome with significant respiratory compromise each time\n  3. Sickle nephropathy\n  4. Recurrent admissions for vaso-occlusive episodes resulting in prolonged opioid use and poor quality of life with interrupted school attendance activity\n  5. Red cell alloimmunization with the need for chronic transfusions\n  6. Recurrent osteonecrosis or multiple joint involvement from avascular necrosis\n* Patients with sickle cell disease must have hemoglobin S \\\u003C 30% within 30 days prior to beginning alemtuzumab\n* Age \\\u003C\u002F= 20.99 years at the time of enrollment\n* Performance score \\>\u002F= 50\n* Left ventricular ejection fraction \\> 40% or left ventricular shortening fraction \\> 26% by echocardiogram\n* DLCO \\> 40% (corrected for hemoglobin) or pulse oximetry with a baseline O2 saturation of \\>\u002F= 90% on room air if too young to perform PFTs\n* Serum creatinine \\\u003C\u002F= 1.5x upper limit of normal for age and\u002For GFR \\> 70 mL\u002Fmin\u002F1.73m2\n* Direct bilirubin \\\u003C 2x upper limit of normal for age\n* ALT and AST \\\u003C 5x upper limit of normal for age\n* Participants who have or are receiving \\>\u002F= 8 packed red blood cell transfusions for \\>\u002F= 1 year or \\>\u002F= 20 packed red blood cell transfusions (lifetime cumulative) will undergo liver MRI for estimation of hepatic iron content.\n\n  1\\. Liver biopsy is indicated for hepatic iron content \\>\u002F= 7mg Fe\u002Fmg liver dry weight by liver MRI. Histologic examination of the liver must document for the absence of cirrhosis, bridging fibrosis, and active hepatitis\n* Female subjects of childbearing potential, must agree to practice 2 methods of contraception at the same time from the time of signing of informed consent through 12 months post transplant. Male subjects must agree to practice effective barrier contraception or practice true abstinence from the time of signing informed consent through 12 months post transplant.\n* Written informed consent must be obtained from all recipients in accordance with the guidelines of the institution's Human Studies Committee.\n\nExclusion Criteria:\n\n* Patients who have an HLA-identical sibling who is able and willing to donate bone marrow\n* Patients with cirrhosis or established bridging fibrosis of the liver or active hepatitis\n* Uncontrolled bacterial, viral, or fungal infection within 6 weeks prior to enrollment\n* Evidence of HIV infection or known HIV positive serology\n* Patients who have received a previous stem cell transplant\n* Patients who have received an investigational drug or device or off-label use of a drug or device within 3 months of enrollment\n* Females who are pregnant or breast feeding\n* Patients with active autoimmune disease (e.g. sarcoidosis, lupus, scleroderma)","1 Day","21 Years",{"count":136,"type":19},29,[138,139],"PHASE1","PHASE2","This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.",[142,143,25,144,145,146],"Severe Sickle Cell Disease","Bone Marrow Failure Syndromes","Immunologic Disorders","Hemoglobinopathies","Non-malignant Disorders",[148,149,150,151,152],"Bone marrow transplant","Transplant","Transplantation","Reduced Intensity","Familial HLA mismatched","2026-05-26",{"date":155,"type":34},"2026-05-29",{"date":157,"type":34},"2017-03-20",{"date":159,"type":19},"2033-04",{"name":161,"class":162},"Washington University School of Medicine","OTHER",4,{"id":165,"slug":4,"hasResults":10,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":10,"sex":14,"minAge":90,"maxAge":16,"enrollmentInfo":171,"targetDuration":4,"studyType":93,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100636210","NCT07562724","Diet and WB-EMS Effects in Obesity","Effects of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) on Myokine-Adipokine Interaction, Appetite Regulation, and Body Composition in Obese Individuals: A Randomized Controlled Trial","DEMO-OB","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥ 30 kg\u002Fm²\n* Sedentary lifestyle (less than 2 hours of structured exercise per week)\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of pacemaker or implantable cardioverter-defibrillator\n* Known cardiovascular disease or severe chronic illness\n* Pregnancy or breastfeeding\n* Uncontrolled diabetes or severe metabolic disorders\n* Active malignancy or cancer treatment\n* Severe renal or hepatic failure\n* Acute infection or inflammatory disease\n* Orthopedic conditions limiting physical activity\n* Use of medications affecting body composition or appetite (e.g., corticosteroids, weight-loss drugs)\n* Regular resistance training within the last 3 months\n* Substance abuse, including alcohol or drug dependency\n* Psychiatric or cognitive conditions affecting adherence to the study protocol",{"count":172,"type":19},40,[174],"NA","Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness.\n\nWhole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood.\n\nThis randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks.\n\nPrimary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.",[177,25,178],"Obesity & Overweight","Electrotherapy","2026-05-11",{"date":181,"type":34},"2026-05-14",{"date":183,"type":19},"2026-09-01",{"date":185,"type":19},"2027-06-20",{"name":187,"class":162},"Firat University",2,{"id":190,"slug":4,"hasResults":10,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":10,"sex":14,"minAge":90,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":93,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":42},"100640068","NCT07576777","Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty","Roles of Hormonal Modulation and the Microbiota in Gastric Emptying and Metabolic Response After Endoscopic Sleeve Gastroplasty","HOVIGAMI-ESG","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years\n* BMI between 30 and 40 kg\u002Fm²\n* With or without obesity-related comorbidities (hypertension, diabetes, -obstructive sleep apnea, etc.)\n* Indication for ESG (Endoscopic Sleeve Gastroplasty) or surgical sleeve gastrectomy validated in a multidisciplinary team meeting\n* Patient with an indication to undergo CT scan and scintigraphy\n* Written informed consent\n* Affiliation with a health insurance system\n\nExclusion Criteria:\n\n* Patient receiving anti-obesity treatment (GLP-1 analogs, multi-agonists)\n* History of prior gastric surgery\n* History of gastric or distal esophageal cancer\n* History of gastric dysplasia\n* Presence of a hiatal hernia \\> 2 cm\n* Contraindication to general anesthesia, including:\n\n  * Severe coagulation disorders, including uncontrolled congenital or acquired hemostasis disorders, severe thrombocytopenia (platelets \\\u003C 50 G\u002FL), non-interruptible anticoagulant or antiplatelet therapy according to current guidelines, uncorrected INR \\> 1.5\n  * Hemodynamic instability, defined as persistent hypotension or shock, uncontrolled cardiac arrhythmias, or need for vasopressor support\n  * Decompensated cardiac disease, including uncontrolled heart failure (NYHA III-IV), unstable ischemic heart disease or recent acute coronary syndrome, untreated severe valvular disease, uncontrolled severe hypertension\n  * Decompensated respiratory disease, including acute or severe chronic respiratory failure not stabilized, uncontrolled severe COPD, untreated severe obstructive sleep apnea, persistent hypoxemia requiring high-flow oxygen therapy\n  * Any other clinical condition considered incompatible with general anesthesia or endoscopy by the anesthesiologist or investigator, according to current guidelines and patient safety considerations Significant or unstable renal insufficiency, or history of severe reaction to iodinated contrast agents\n* Participation in another clinical research study, except for non-interventional studies\n* Patient under legal protection (guardianship, curatorship, or judicial protection)\n* Physical inability to provide written informed consent\n* Rare forms of obesity of genetic and\u002For central origin (e.g., associated with craniopharyngioma)\n* Pregnancy or breastfeeding\n* State medical aid (AME)",{"count":172,"type":19},[174],"Obesity is a chronic disease with a rapidly increasing prevalence, expected to affect up to 25% of the French population by 2030, and is associated with significant morbidity, mortality, and healthcare burden. Bariatric surgery, including sleeve gastrectomy and gastric bypass, remains the standard treatment for severe obesity but is irreversible and carries procedural risks.\n\nLess invasive alternatives have emerged, including pharmacological treatments (GLP-1 receptor agonists and multi-agonists) and endoscopic approaches such as endoscopic sleeve gastroplasty (ESG), which have shown efficacy in weight loss and metabolic improvement, although drug therapies are limited by weight regain after discontinuation.\n\nSleeve gastrectomy, the most frequently performed bariatric procedure in France, induces weight loss through gastric restriction and hormonal changes, including decreased ghrelin and increased GLP-1 and PYY, along with accelerated gastric emptying.\n\nESG is a minimally invasive endoscopic technique with mechanisms that remain incompletely understood, likely involving gastric restriction, altered gastric emptying, and hormonal and microbiome-related effects.\n\nBariatric outcomes are driven by complex interactions between gastric anatomy, motility, hormonal regulation, and the gut microbiome. An integrated evaluation of these parameters is needed to better understand response variability after intervention.\n\nA total of 40 patients will be enrolled (20 per group).",[200,25],"Obesity (Disorder)",[23,202,203,204,205,206,207,208],"Endoscopic Sleeve Gastroplasty","Sleeve Gastrectomy","Gastric Emptying","Gut Hormones","Gastric Microbiota","Weight Loss","Metabolic Response","2026-05-04",{"date":211,"type":34},"2026-05-08",{"date":209,"type":19},{"date":214,"type":19},"2029-05-04",{"name":216,"class":162},"Assistance Publique - Hôpitaux de Paris",{"id":218,"slug":4,"hasResults":10,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":60,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":222,"targetDuration":224,"studyType":20,"phases":4,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":42},"100632355","NCT07512609","Environment, Inflammation and Metabolic Diseases Study","Inclusion Criteria:\n\n* All individuals who voluntarily participated in the physical examination\n\nExclusion Criteria:\n\nParticipants with incomplete data",{"count":223,"type":19},8000,"5 Years","The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.",[227,25,228,229],"Endocrine Disease","Hypertension","Diabetes Mellitus",[227,25,228,229],"2026-04-01",{"date":233,"type":34},"2026-04-06",{"date":235,"type":34},"2020-12-25",{"date":237,"type":19},"2026-12-31",{"name":239,"class":162},"Qifu Li",{"id":241,"slug":4,"hasResults":10,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":93,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100126972","NCT00920972","Campath\u002FFludarabine\u002FMelphalan Transplant Conditioning for Non-Malignant Diseases","A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime","Inclusion Criteria:\n\nStratum 1: Patient must have non-malignant disorder, excluding thalassemia. Must be receiving a 8\u002F8 HLA-matched bone marrow, related or unrelated Stratum 2: Patient must have thalassemia receiving 8\u002F8 HLA-matched bone marrow or 5-8\u002F8 HLA-matched UCB. Related or unrelated.\n\nStratum 3: Patient must have a hemoglobinopathy receiving 7\u002F8 HLA-matched bone marrow or 5-8\u002F8 HLA-matched UCB. Related or unrelated.\n\nStratum 4: Patient must have a non-malignant disorder (excluding hemoglobinopathy) receiving 7\u002F8 HLA-matched bone marrow or 5-8\u002F8 HLA-matched UCB. Related or unrelated.\n\nAll strata:\n\n* Recipient age \\\u003C 21 years\n* Lansky\u002FKarnofsky \\>\u002F= 40\n* Adequate pulmonary, renal, liver, and other organ function as defined in protocol\n* Negative pregnancy test\n* Adequate total nucleated cell or CD34+ dose of product as defined in protocol\n* If sickle cell, Hemoglobin S \\\u003C30%\n\nExclusion Criteria:\n\n* HIV positive\n* Invasive infection\n* Pregnancy\u002Flactating","20 Years",{"count":248,"type":19},220,[138,139],"The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.",[25,252,145,146],"Hematologic, Immune, or Bone Marrow Disorders",[254,149,150,255,256,257,258,259,260,261,262,263],"Bone marrow","Hematopoietic","Umbilical cord","Related","Unrelated","Reduced","Non-myeloablative","Nonmyeloablative","Non-malignant","Nonmalignant","2026-03-24",{"date":266,"type":34},"2026-03-25",{"date":268,"type":34},"2001-12",{"date":270,"type":19},"2031-12",{"name":161,"class":162},28,{"id":274,"slug":4,"hasResults":10,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":60,"sex":14,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":93,"phases":284,"briefSummary":285,"conditions":286,"keywords":293,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":42},"100620766","NCT07361887","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles","(WINEVOME)","Inclusion Criteria\n\n* Healthy adult men and women aged 35 to 65 years.\n* Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n* Non-smokers or ex-smokers for at least 12 months.\n* Moderate alcohol consumers, defined as ≤2 units\u002Fday for men and ≤1 unit\u002Fday for women.\n* Normal fasting glucose and lipid profile at screening.\n* Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria\n\n* History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension).\n* Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, corticosteroids, anti-inflammatory drugs).\n* Pregnancy or breastfeeding.\n* Recent blood donation (within the last 3 months) or planned blood donation during the study period.\n* Major weight change (\\>5% of body weight) within the last 3 months.\n* Participation in another clinical or biomedical study within the previous 3 months.\n* Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites).\n* History of alcohol abuse or inability to abstain from alcohol outside the study context.\n* Reluctance to receive information about incidental health findings arising from the study.\n* Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).","35 Years","36 Years",{"count":283,"type":19},8,[174],"This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.",[287,23,288,25,289,290,291,292],"Atherosclerosis Cardiovascular Disease","Metabolic Syndrome","Inflammation","Neurodegeneration","Neurodegenerative Disease","Alzheimer s Disease",[294,295,296,297,298,299],"blood-brain barrier","microglia","extracellular vesicles","lipidome","proteome","vascular disease","2026-01-14",{"date":302,"type":34},"2026-01-23",{"date":304,"type":34},"2025-11-01",{"date":306,"type":19},"2027-03-31",{"name":308,"class":162},"University of Seville",{"id":310,"slug":4,"hasResults":10,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":10,"sex":14,"minAge":90,"maxAge":4,"enrollmentInfo":316,"targetDuration":224,"studyType":20,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100616769","NCT07309913","China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort)","China Atrial Fibrillation With Complex Metabolic Disorders Cohort Study (CAME Cohort)","CAME Cohort","Inclusion Criteria\n\n* Meet the diagnostic criteria for atrial fibrillation: Single-lead electrocardiogram (≥30 seconds) or 12-lead electrocardiogram (≥10 seconds) shows disappearance of P waves, replaced by fibrillation waves (f waves) with irregular amplitude, morphology and duration, and absolutely irregular RR intervals.\n* Aged ≥ 18 years.\n* Willing to sign the informed consent form and cooperate with long-term follow-up.\n\nExclusion Criteria\n\n* Suffering from infective endocarditis or myocarditis.\n* Having clear etiological factors of atrial fibrillation caused by hyperthyroidism, and the etiology has not been effectively controlled.\n* Suffering from severe mental illness and being unable to comply with the study requirements.\n* Pregnant women.\n* Patients with malignant tumors or substance abuse (e.g., cocaine, heroin).",{"count":317,"type":19},3459,"The number of atrial fibrillation (AF) patients in China is approximately 32.76 million, with a prevalence rate of 2.3%. AF is associated with severe outcomes such as stroke and heart failure. Metabolic disorders (e.g., obesity, diabetes mellitus, dyslipidemia) are closely linked to the onset and prognosis of AF. However, the epidemiological characteristics and disease burden of AF combined with metabolic disorders in China remain unclear. Additionally, the impact of complex multi-dimensional metabolic disorders on AF prognosis requires further investigation, and current clinical guidelines lack targeted management recommendations for this population.",[320,25],"Atrial Fibrillation (AF)","2025-12-15",{"date":323,"type":34},"2025-12-30",{"date":325,"type":19},"2026-02-01",{"date":327,"type":19},"2036-06-01",{"name":329,"class":162},"Xiangya Hospital of Central South University",{"id":331,"slug":4,"hasResults":10,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":10,"sex":14,"minAge":90,"maxAge":4,"enrollmentInfo":337,"targetDuration":339,"studyType":20,"phases":4,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":42},"100608847","NCT07206875","Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders","Retrospective and Prospective Observational Registry for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine-metabolic Disorders","DiabRegistry","Inclusion Criteria:\n\n* Age ≥18 years\n* Outpatient Diabetes Unit patient\n* Ability to give informed consent\n\nDiagnosis of at least one of the following:\n\n* Metabolic disease, defined as BMI ≥25 Kg\u002Fm2\n* Type 1 or type 2 diabetes mellitus\n* Gestational diabetes\n* Monogenic diabetes (MODY)\n* Other types of diabetes or dysglycemia\n* Dyslipidemia\n* Arterial hypertension\n* Steatosis liver disease (SLD)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Deny participation at the study\n* Recruitment in an interventional protocol\n* Patients with missing significant data",{"count":338,"type":19},10000,"10 Years","The main objective of this retrospective and prospective observational register is to identify anthropometric, clinical, laboratory and\u002For instrumental markers of disease severity and activity in patients suffering from diabetes, endocrine-metabolic disorders, rare diseases in order to improve their diagnosis, monitoring and treatment processes. The Registry is monocentric, observational prospective and retrospective. No additional procedures to those of normal clinical practice are planned, and neither diagnostic approaches nor experimental drugs\u002Fprescriptions will be applied. The data under study (demographic, anthropometric, clinical and care characteristics) will be collected as part of outpatient visits of the Diabetes Outpatient Clinic or admission to Diabetes Day Hospital.\n\nIn case of outpatients, the observation will start at the diagnosis or during the first outpatient visit and will end with the last outpatient visit performed within the total time foreseen for the duration of the study.\n\nThe study will start once the regulatory authorizations are completed, and is expected to last at least 10 years with the possibility of extension",[24,25,342,343,344],"Arterial Hypertension","Dyslipidemia","Liver Disease (Alcoholic or Not)",[346,347,348,349],"diebetes","metabolic disorders","endocrine disorders","observational study","2025-10-01",{"date":352,"type":34},"2025-10-03",{"date":354,"type":19},"2025-11",{"date":356,"type":19},"2035-11",{"name":358,"class":162},"IRCCS San Raffaele",{"id":360,"slug":4,"hasResults":10,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":60,"sex":14,"minAge":90,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":42},"100605364","NCT07161557","Evaluating Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index","An Open Observational Study to Evaluate Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index","Inclusion Criteria:\n\n* Male and female volunteers, aged 18 to 60, regardless of gender;\n* Not participating in other interventional clinical studies;\n* Have a good understanding of the nature, purpose, benefits obtained, and possible risks and side effects of the study;\n* Willing to comply with all trial requirements and procedures;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* In the treatment of gastrointestinal symptoms;\n* Those who are lactose intolerant, allergic to fish and their products;\n* Current suffering from other organic diseases affecting bowel function, such as history of gastrointestinal resection, colon or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.;\n* Diet control, exercise enhancement, or taking medications that control weight or affect appetite in the past 3 months;\n* Volunteers have any of the following medical history or have been clinically diagnosed with the following diseases that may affect the evaluation of the test results: obvious gastrointestinal disorders, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;\n* Current or past abuse of alcohol or other illicit drugs, supplements, or OTC prescriptions 3 \u002F 11 Research content Collection of biological samples or information data Evaluation indicators Drugs may cause intestinal dysfunction or affect the evaluation of trial effects;\n* Frequent use of drugs that may affect gastrointestinal function or immune system according to the investigator's judgment.","60 Years",{"count":367,"type":19},200,"The goal of this observational study is to evaluate Metabolic Health by fit analysis between calculated Nutrilite Metabolic Health Index and the result of Metabolomics analysis from blood plasma samples in healthy adult participants aged between 18 and 60 years. The main question it aims to answer:\n\n\\- Does the Nutrilite Metabolic Health Index fit well with the result of Metabolomics analysis from blood plasma samples?\n\n200 eligible participants will be enrolled in a single center, one site visit will be made to finish a health questionnaire, a lifestyle questionnaire, a routine physical checkup. Blood samples will be collected for routine blood test (blood sugar, total triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid), and for Metabolomics testing.\n\nResearchers will calculate the Nutrilite Metabolic Health Index based on participant data, and do the fit analysis against the result from Metabolomics analysis.",[370,25],"Metabolic Abnormality",[372,373,374,375],"Diet2Me","Nutrilite Metabolic Health Index","Metabolic health omics model","Metabolomics testing","2025-09-07",{"date":378,"type":34},"2025-09-12",{"date":380,"type":19},"2025-10-09",{"date":382,"type":19},"2026-05-10",{"name":384,"class":124},"Amway (China) R&D Center",{"id":386,"slug":4,"hasResults":10,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":60,"sex":14,"minAge":365,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":393,"conditions":394,"keywords":398,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":42},"100602548","NCT07124949","Chinese Migrant Population Health Cohort","Inclusion Criteria:\n\n1. Permanent residents of Harbin or Hainan who will continue to reside in Harbin or Hainan for the next 5 years.\n2. Baseline age ≥60 years, with basic communication and comprehension abilities.\n3. No confirmed diagnosis of end-stage major organic diseases (e.g., advanced heart failure, advanced liver failure, advanced kidney failure, malignant tumors).\n4. Able to perform activities of daily living independently and capable of completing questionnaires and physical examinations.\n5. Willing to participate in the study, provide written informed consent, accept long-term follow-up, and provide biological specimens.\n\nExclusion Criteria:\n\n1. Occurrence of life-threatening acute events (e.g., myocardial infarction, acute heart failure, stroke) within the past 30 days.\n2. Currently receiving chronic treatment with antiviral drugs (e.g., for HIV) or antipsychotic medications.\n3. Presence of moderate to severe cognitive impairment preventing survey completion or follow-up cooperation.\n4. Current acute infectious diseases such as influenza or fever.\n5. Simultaneous participation in other interventional clinical studies.\n6. Refusal to sign informed consent or unwillingness to provide biological specimens.\n7. Any other condition deemed unsuitable for study participation by the investigators based on overall assessment.","120 Years",{"count":392,"type":19},26000,"The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.\n\nParticipants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.\n\nThe study aims to:\n\nDefine migration-related health risk profiles and disease phenotypes.\n\nElucidate biological and environmental mechanisms influencing disease onset and progression.\n\nDevelop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.\n\nTranslate findings into clinical guidelines and scalable cross-regional health management models.\n\nThis is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.",[395,25,396,397],"Cardiovascular Diseases","Ageing and Geriatric Health","Climate Adaptation",[395,399,400,401,402,403],"Metabolic Diseases","Geriatrics","Migration","Climate Change","Health Promotion","2025-08-14",{"date":406,"type":34},"2025-08-20",{"date":408,"type":34},"2025-07-23",{"date":410,"type":19},"2030-04-30",{"name":412,"class":162},"Jinwei Tian",{"id":414,"slug":4,"hasResults":10,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":60,"sex":14,"minAge":90,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":93,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":42},"100580816","NCT06842225","Interactive Roles of Cardiorespiratory Fitness and Adiposity on Glucose and Vascular Control After Physical Inactivity","Interactive Roles of Cardiorespiratory Fitness and Adiposity on Recovery of Impaired Glucose and Vascular Control After Physical Inactivity","Inclusion Criteria:\n\n* Males and females 18 to 40 years of age.\n* Ability to safely ride an electric scooter (e-scooter) for at least 10 minutes.\n* Active (\\>7000 steps per day, walking \\> 1 mile a day outside)\n* Stable body weight for at least 1 year\n* aerobic fitness level, CRF is \\\u003C 9 and \\>14 METS\n* Visceral adipose tissue \\\u003C130 cm2 or ≥130 cm2 for men and \\\u003C100 cm2 or ≥100 cm for women\n\nExclusion Criteria:\n\n* Any injury preventing them from exercising regularly at the time of the screening.\n* Implantable defibrillator or pacemaker\n* Active cancer\n* Alcohol or drug abuse\n* Use of an assistive walking device\n* Presence of significant signs\u002Fsymptoms of cardiovascular, metabolic, or pulmonary disease (determined from the American College of Sports Medicine (ACSM) Health History Questionnaire)\n* Daily vitamin consumption of \\> 500mg per day during the study\n* Acetaminophen or aspirin use during the study","40 Years",{"count":421,"type":19},48,[174],"The far-reaching negative health effects of the reduced physical activity (RPA) epidemic are often overlooked by the general population and health professionals. Short-term RPA induces cardiometabolic dysfunction, including impaired glucose control and vascular function, that may precede disease development. The impact of existing health status on RPA-induced cardiometabolic dysfunction and recovery of impaired glucose control following RPA is unexplored. Thus, the investigators' objectives are 1) to investigate the effect of existing health status (cardiorespiratory fitness and adiposity) on the recovery of impaired glucose control following a period of RPA and 2) to determine the role of vascular function as a mechanism of impaired glucose control. The investigators' final objective is to 3) expose undergraduate students to meritorious biomedical clinical research methods. The investigators have piloted the clinical research methods and analysis with undergraduate researcher associates and are well-prepared to complete this proposal. Preliminary data show that low cardiorespiratory fitness and\u002For high adiposity impair the recovery of glucose control following short-term RPA. Thus, the investigators aim to examine the interactive role of health status (cardiorespiratory fitness and adiposity) on the ability to recover impaired glucose control following short-term RPA. The investigators also seek to examine changes in vascular function as a mechanism of recovery of impaired glucose control following a return to normal PA. The investigators will recruit men and women with divergent health status (cardiorespiratory fitness and adiposity) to examine glucose control and vascular function during 7-d of normal PA, 7-d of RPA, and 7-d of resumption of normal RA. Continuous glucose monitoring and oral glucose tolerance tests will be performed to assess glucose control. Increases in vascular shear stress induced by passive leg movement and central arterial stiffness will be measured to assess vascular function.",[25,425,426],"Physical Inactivity","Vascular Disease Risk",[428,429,430],"physical activity","glucose control","vascular function","2025-02-18",{"date":433,"type":34},"2025-02-24",{"date":435,"type":19},"2025-06-01",{"date":437,"type":19},"2029-06-30",{"name":439,"class":162},"Miami University",{"id":441,"slug":4,"hasResults":10,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":60,"sex":14,"minAge":90,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":93,"phases":449,"briefSummary":450,"conditions":451,"keywords":456,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":42},"100558748","NCT06555159","Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.","EFFECT OF AN AEROBIC EXERCISE PROGRAM ON METABOLIC DISORDERS LEVELS IN HIGHER EDUCATION STUDENTS AT THE UNIVERSITY OF COLIMA, RANDOMIZED CLINICAL TRIAL.","(EPE_RCTMCS)","Inclusion Criteria:\n\n* University of Colima students linked to the central campus.\n* Students aged between 18 and 25 years old.\n* Authorization to participate in the project with a signed informed consent.\n* Suffer from at least one of the parameters of metabolic disorders or cardiovascular risk (Hyperglycemia, decreased DHL, elevated triglycerides, abdominal obesity or hypertension) following the clinical assessment (Considering the criteria established by the ADA and ATPIII).\n\nExclusion Criteria:\n\n* Motor limitations that may hinder the performance of physical exercise.\n* Pregnancy or lactation.\n* High Vigorous Physical Activity Level according to the IPA-Q.\n* To be currently under pharmacological treatment to manage altered metabolic levels.\n\nELIMINATION CRITERIA\n\n* Musculoskeletal injuries during the study period.\n* Unforeseen Medical Events: Unexpected medical situations that could influence study results, such as hospitalizations, serious illnesses, or surgeries.\n* Non-Compliance with Follow-Up: Subjects failing to meet a minimum of 80% (19 out of 24 sessions) of the stipulated physical conditioning program time.\n* Initiation of clinical treatment that may affect protocol results, such as medications that reduce alterations.\n* Participants who voluntarily withdraw from the study.","25 Years",{"count":421,"type":19},[174],"This clinical trial objective is to evaluate the effect of an aerobic physical exercise program on reducing triglycerides, blood pressure, abdominal obesity, altered glucose levels, and the increase in HDL in college-level students at the University of Colima. It will try to answer whether aerobic physical exercise reduces metabolic disorders (altered blood pressure and glucose levels, abdominal obesity, and increased HDL). A simple randomized clinical trial will be conducted with a sample of 48 voluntary students from the University of Colima, divided into two groups of 24 people (Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax; and Experimental Group -B-, will undergo an aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload).\n\nResearchers will compare the results of both groups to confirm the effectiveness of the planned aerobic physical exercise in reducing these risks.",[25,452,453,454,28,455],"Abdominal Obesity","Blood Pressure Disorders","Hypertriglyceridemia","HDL-Deficiency",[457,23,458,459,228],"Exercise","HDL","Triglycerides","2024-08-12",{"date":462,"type":34},"2024-08-15",{"date":464,"type":19},"2024-09",{"date":466,"type":19},"2025-06",{"name":468,"class":162},"Universidad de Colima",{"id":470,"slug":4,"hasResults":10,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":10,"sex":14,"minAge":16,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":93,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":493},"100543611","NCT06358118","Buyuan-zhixiao Formula in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders","Clinical Research on Evidence Based Traditional Chinese Medicine for Elderly Diabetes Based on State Target Theory-Buyuan Zhixiao Fang in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders: Study Protocol for a Multicenter, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* 1.Age ≥65 years, irrespective of sex;\n* 2.Individuals who meet the Western medical diagnostic criteria for type 2 diabetes mellitus (T2DM) in the elderly, with a hemoglobin A1c level of ≥7.0% in the past three months;\n* 3.Compliance with the diagnostic criteria for abdominal obesity (waist circumference ≥90 cm for males and ≥85 cm for females);\n* 4.Conformity to the diagnostic standards for hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg);\n* 5.A history of dyslipidemia, where lipid levels have not reached the general control standards for elderly individuals with T2DM following oral lipid-lowering therapy (statins\u002Fbile acid sequestrants): LDL cholesterol \\\u003C2.6 mmol\u002FL and\u002For triglycerides \\\u003C2.5 mmol\u002FL;\n* 6.Diagnosis of kidney deficiency and blood stasis according to traditional Chinese medicine, with the pattern type referring to the《Guidelines for Clinical Research of New Chinese Medicines》;\n* 7.Willingness to sign an informed consent document.\n\nExclusion Criteria:\n\n* 1.Exclusion of individuals who, within the past week, have experienced severe infections, acute cardiovascular or cerebrovascular events (such as acute cerebral infarction or myocardial infarction), significant trauma, acute pancreatitis, or other conditions that could precipitate stress-induced hyperglycemia. This also extends to those with concurrent endocrinopathies that may induce insulin resistance, such as Cushing's syndrome, hyperthyroidism, or pituitary growth hormone adenomas, as well as those currently receiving treatment with glucocorticoids or undergoing chemotherapy for malignancies.\n* 2.Exclusion of individuals with a history of neurological disorders or psychiatric conditions that could impair cognitive function, as well as those with a history of medication use for these conditions.\n* 3.Exclusion of individuals with severe complications of diabetes such as diabetic nephropathy in the uremic stage, or those with significant primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, as well as individuals diagnosed with cancer.\n* 4.Exclusion of individuals with communication barriers that could affect the assessment of cognitive function, including severe impairments in speech, vision, and hearing.\n* 5.Individuals who have participated in other pharmacological clinical trials within the past month.\n* 6.Individuals who have insufficient understanding of this study, are unwilling to participate, or, based on the researchers' judgment, present a reduced likelihood of enrollment or poor compliance due to unstable work and living locations or other factors that could lead to loss to follow-up.",{"count":476,"type":19},240,[174],"The primary objective of this clinical trial is to assess the clinical efficacy and safety of the Buyuan Zhixiao Formula in treating elderly patients with diabetes and multiple metabolic disorders exhibiting symptoms of renal deficiency and blood stasis. Furthermore, this study aims to intervene in high-risk factors to prevent arteriosclerosis and to investigate the clinical efficacy of the Buyuan Zhixiao Formula in the prevention and treatment of cognitive impairments.\n\nThe main questions it aims to answer are:\n\n1. What are the clinical effects of Buyuan Zhixiao Formula, including lowering blood sugar, lowering blood pressure, lowering lipids, and treating obesity?\n2. Can Buyuan Zhixiao Formula improve cognitive impairment in diabetes? Researchers compared Buyuan Zhixiao Formula with a placebo (a drug that looks similar but contains only 10% of the active ingredients) to see if the drug Buyuan Zhixiao Formula can treat elderly people with diabetes and multiple metabolic disorders.\n\nParticipants will:\n\n1. Take the drug Bu Yuan Zhi XiaoFormula or placebo every day for 6 months；Follow-up for 6 months；\n2. Check fasting blood sugar and 2-hour postprandial blood sugar every month; check HbA1c, blood lipids, vascular function, and cognitive impairment serum markers every 3 months;\n3. Conduct scores on TCM symptoms, cognitive ability, nutritional status and other scales and adverse events;\n4. Urine and serum samples were collected before and after treatment;",[480,481,25,482,483],"Diabete Mellitus","Aging","Traditional Chinese Medicine","Randomized Controlled Trial","2024-06-02",{"date":486,"type":34},"2024-06-04",{"date":488,"type":19},"2024-07-06",{"date":490,"type":19},"2025-07-01",{"name":492,"class":162},"Qing Ni",6,""]